



October 30, 2026

Consolidated Financial Results for the First Six Months of the Year Ending March 31, 2027 (Fiscal 2026) <under IFRS>

Listed company name: Daiichi Sankyo Company, Limited

Listed exchange: the Tokyo Stock Exchange

Stock code number: 4568

URL: <https://www.daiichisankyo.com>

Representative: Mr. Hiroyuki Okuzawa, Representative Director, President and CEO

Contact: Ms. Ari Fujishiro, Corporate Officer, Head of Investor Relations and Shareholder Relations Department

Telephone: +81-3-6225-1125

Scheduled date to file semi-annual securities report: November 6, 2026

Scheduled date to commence dividend payments: December 10, 2026

Preparing supplementary material (Reference Data) on quarterly financial results: Yes

Holding of financial results briefing: Yes (for institutional investors, analysts and the press)

(All amounts have been rounded down to the nearest million JPY)

1. Consolidated Financial Results for the First Six Months of the Year Ending March 31, 2027 (from April 1, 2026 to September 30, 2026)

(1) Consolidated Financial Results (cumulative)

(Percentages indicate changes from the same period in the previous fiscal year)

	Revenue		Core operating profit		Operating profit		Profit before tax	
	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%
Six months ended September 30, 2026	1,167,233	19.7	221,331	46.9	193,795	34.4	192,855	18.2
Six months ended September 30, 2025	975,353	10.5	150,690	(9.5)	144,237	(22.8)	163,217	(15.2)

	Profit for the period		Profit attributable to owners of the Company		Total comprehensive income		Basic earnings per share	Diluted earnings per share
	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	JPY	JPY
Six months ended September 30, 2026	153,056	17.0	151,534	15.8	143,679	3.0	83.22	83.20
Six months ended September 30, 2025	130,814	(10.8)	130,814	(10.8)	139,509	26.7	70.55	70.52

Note: Daiichi Sankyo discloses core operating profit, which excludes non-core income and expenses from operating profit, as an indicator of underlying profitability. For the definition of core operating profit, please refer to "1. Results of Operations (1) Operating Results for the first six months of the year ending March 31, 2027" on page 2 of the attached material.

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the Company	Ratio of equity attributable to owners of the Company to total assets	Equity per share attributable to owners of the Company
	Millions of JPY	Millions of JPY	Millions of JPY	%	JPY
As of September 30, 2026	4,258,626	1,780,121	1,757,648	41.3	964.65
As of March 31, 2026	3,996,285	1,684,033	1,684,033	42.1	925.47

2. Cash Dividends

	Annual dividend per share				
	First quarter	Second quarter	Third quarter	Fiscal year-end	Total
	JPY	JPY	JPY	JPY	JPY
Fiscal year ended March 31, 2026	—	39.00	—	39.00	78.00
Fiscal year ending March 31, 2027	—	50.00			
Fiscal year ending March 31, 2027 (Forecast)			—	50.00	100.00

Note: Revision to the forecast of cash dividends from most recently announced figures: None

3. Forecast of Consolidated Financial Results for Year Ending March 31, 2027

(Percentages indicate changes from the previous fiscal year)

	Revenue		Core operating profit		Operating profit		Profit before tax		Profit for the year	
	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%
Full year	2,340,000	10.2	360,000	15.6	320,000	24.0	334,000	14.2	254,000	(9.2)

	Profit attributable to owners of the Company		Basic earnings per share
	Millions of JPY	%	JPY
Full year	251,000	(10.3)	137.94

Note: Revision to the forecast from most recently announced figures: None

*Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and changes in accounting estimates

- 1) Changes in accounting policies required by IFRS: None
- 2) Changes in accounting policies due to other reasons: None
- 3) Changes in accounting estimates: None

(3) Number of ordinary shares issued

1) Number of issued shares at the end of the period (including own shares)

As of September 30, 2026	1,862,893,329 shares
As of March 31, 2026	1,894,350,529 shares

2) Number of own shares at the end of the period

As of September 30, 2026	40,827,459 shares
As of March 31, 2026	74,697,299 shares

3) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2026	1,820,879,895 shares
Six months ended September 30, 2025	1,854,172,123 shares

* The Japanese-language originals of the semi-annual financial results are exempt from review by certified public accountants or an audit firm

*Disclaimer regarding forward-looking information including appropriate use of forecast financial results

The forecast information included in these materials is based on information currently available and certain assumptions that Daiichi Sankyo regards as reasonable. Actual performance and results may differ from those forecasts due to various factors.

Please see “1. Results of Operations (3) Information about Forecasts of Consolidated Financial Results and Other Forward-Looking Statements” on page 8 for matters related to the above forecasts.

Attached Material

Index

1. Results of Operations	2
(1) Operating Results for the first six months of the year ending March 31, 2027	2
1) Overview	2
2) Status of R&D	5
(2) Analysis of Financial Position as of September 30, 2026	8
(3) Information about Forecasts of Consolidated Financial Results and Other Forward-Looking Statements	8
(4) Information about Return to Shareholders	8
2. Condensed Interim Consolidated Financial Statements with Primary Notes	9
(1) Condensed Interim Consolidated Statement of Financial Position	9
(2) Condensed Interim Consolidated Statement of Profit or Loss and Condensed Interim Consolidated Statement of Comprehensive Income	11
Condensed Interim Consolidated Statement of Profit or Loss	11
Condensed Interim Consolidated Statement of Comprehensive Income	12
(3) Condensed Interim Consolidated Statement of Changes in Equity	13
(4) Condensed Interim Consolidated Statement of Cash Flows	15
(5) Notes to Condensed Interim Consolidated Financial Statements	17
Going Concern Assumption	17
Changes in Presentation	17
Operating Segment Information	17
Significant Subsequent Events	17

1. Results of Operations

(1) Operating Results for the first six months of the year ending March 31, 2027

1) Overview

[Consolidated Financial Results (Core Base)]

(Millions of JPY; all amounts have been rounded down to the nearest million JPY.)

	Six months ended September 30, 2025	Six months ended September 30, 2026	YoY change
Revenue	975,353	1,167,233	191,879 19.7%
Cost of sales*	238,685	239,758	1,073 0.4%
Selling, general and administrative expenses*	369,156	466,087	96,930 26.3%
Research and development expenses*	216,820	240,055	23,235 10.7%
Core operating profit*	150,690	221,331	70,640 46.9%
Non-core income*	4,316	133	(4,183) (96.9%)
Non-core expenses*	10,769	27,670	16,900 156.9%
Operating profit	144,237	193,795	49,557 34.4%
Profit before tax	163,217	192,855	29,638 18.2%
Profit attributable to owners of the Company	130,814	151,534	20,720 15.8%
Total comprehensive income	139,509	143,679	4,169 3.0%

* Daiichi Sankyo Group (hereinafter, “the Group”) has changed the definition of core operating profit starting from the fiscal year ending March 2027. Under the new definition, core operating profit is disclosed as an indicator of the fundamental profitability of the business, excluding the following items from operating profit.

- Amortization expenses of intangible assets related to products
- Gains/losses associated with restructuring
- Impairment losses on property, plant and equipment, intangible assets, and goodwill
- Gains/losses related to damages and settlements
- Acquisition-related costs
- Loss (gain) on exchange differences (applicable from the fiscal year ending March 31, 2028)
- Other gains/losses that the Company deems should be excluded to understand the fundamental profitability of the Group’s business

Please note that the core operating profit for the fiscal year ending March 2026, as listed in this table, also reflects this change in definition. The adjustment table from operating profit to core operating profit is stated in the Reference Data.

<JPY exchange rates for major currencies (average rate for year)> (JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
USD/JPY	146.04	159.37
EUR/JPY	168.06	184.35

a. Revenue

- Revenue in the first six months of the year ending March 31, 2027 increased by JPY191.9 billion, or 19.7% year on year, to JPY1,167.2 billion.
- Revenue increased year on year due to the growth of global mainstay products such as Enhertu (generic name: trastuzumab deruxtecan, T-DXd/DS-8201) and Datroway (generic name: datopotamab deruxtecan: Dato-DXd/DS-1062), as well as the positive effect from foreign exchange by the depreciation of JPY.
- The positive effect on revenue from foreign exchange was JPY73.9 billion in total.

b. Core operating profit

- Core operating profit increased by JPY70.6 billion, or 46.9% year on year, to JPY221.3 billion.
- Cost of sales was JPY239.8 billion, constituting an increase of JPY1.1 billion, or 0.4% year on year, due to an increase in revenue and the effect from foreign exchange by the depreciation of JPY, although compensation for losses paid to CMO decreased.
- Selling, general and administrative expenses increased by JPY96.9 billion, or 26.3%, to JPY466.1 billion mainly due to the cost increase by an increase in profit sharing with AstraZeneca.
- Research and development expenses increased by JPY23.2 billion, or 10.7% year on year, to JPY240.1 billion due to increased R&D investment in 5DXd ADCs (trastuzumab deruxtecan, datopotamab deruxtecan, patritumab deruxtecan: HER3-DXd/U3-1402, ifinatamab deruxtecan: I-DXd/DS-7300, raludotatug deruxtecan: R-DXd/DS-6000) and the Next Wave (products designed to transform the standard of care).
- The positive effect on core operating profit from foreign exchange was JPY22.7 billion in total.

c. Operating profit

- Operating profit increased by JPY49.6 billion, or 34.4% year on year, to JPY193.8 billion.
- The costs of business reorganization in the EU Specialty Business Unit were recorded as non-core expenses, resulting in a smaller increase compared to core operating profit.
- The positive effect on operating profit from foreign exchange was JPY20.0 billion in total.

d. Profit before tax

- Profit before tax increased by JPY29.6 billion, or 18.2% year on year, to JPY192.9 billion.
- The smaller increase compared to operating profit was a result of an increase of financial expenses.

e. Profit attributable to owners of the Company

- Profit attributable to owners of the Company increased by JPY20.7 billion, or 15.8% year on year, to JPY151.5 billion.

- The increase in profit was smaller than that in profit before tax, mainly due to an increase in income taxes.

f. Total comprehensive income

- Total comprehensive income increased by JPY4.2 billion, or 3.0% year on year, to JPY143.7 billion.
- The smaller increase compared to profit attributable to owners of the Company was a result of the decrease in the currency translation difference related to net assets of overseas subsidiaries and other factors.

[Revenue by Business Unit]

Revenue by business unit in the first six months of the year ending March 31, 2027 is as follows. Revenue by product is stated in the Reference Data.

a. Japan Business Unit

Revenue from Japan Business Unit includes revenue from products generated by the innovative pharmaceuticals business and the vaccine business.

Revenue from the Unit decreased by JPY17.2 billion, or 6.9% year on year, to JPY232.7 billion due to decreases in sales of Lixiana and others, despite the growth of Enhertu, Tarlige and others.

The following describes the major progress in the first six months of the year ending March 31, 2027.

- In September 2026, approval was obtained for Enhertu for the combination therapy with pertuzumab for the first-line treatment for HER2 positive breast cancer, and the promotion started.
- In September 2026, approval was obtained for Datroway for the first-line treatment for hormone receptor negative and HER2 negative breast cancer, and the promotion started.

b. Daiichi Sankyo Healthcare Unit

Revenue from Daiichi Sankyo Healthcare Unit increased by JPY2.4 billion, or 5.1% year on year, to JPY48.3 billion as a result of the increase in sales of Clean Dental, and others.

c. Oncology Business Unit

Revenue from Oncology Business Unit includes revenue from cancer treatment products generated by Daiichi Sankyo, Inc. (the U.S.) and Daiichi Sankyo Europe GmbH.

Revenue from the Unit increased by JPY149.6 billion, or 54.8% year on year, to JPY422.6 billion and the revenue in local currency increased by USD782 million, or 41.9%, to USD2,652 million due to the growth of Enhertu and Datroway in the U.S. and Europe.

The following describes the major progress in the first six months of the year ending March 31, 2027.

- In May 2026, approval was obtained for Enhertu in the U.S. for indications in the neoadjuvant and adjuvant settings of patients with HER2 positive early breast cancer, and the promotion started.
- In May 2026, approval was obtained for Datroway in the U.S. for first-line treatment of patients with triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, and the promotion started.
- In June 2026, approval was obtained for Enhertu in Europe for patients with multiple HER2 positive solid tumors, and the promotion started.

- In July 2026, approval was obtained for Datroway in Europe for first-line treatment of patients with triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, and the promotion started.
- In September 2026, approval was obtained for Enhertu in Europe for the combination therapy with pertuzumab for the first-line treatment for HER2 positive breast cancer, and the promotion started.

d. American Regent Unit

Revenue from American Regent Unit decreased by JPY18.9 billion, or 19.5% year on year, to JPY77.9 billion and the revenue in local currency decreased by USD174 million, or 26.3%, to USD489 million due to decreases in sales of Venofer, Injectafer, etc.

e. EU Specialty Business Unit

Revenue from EU Specialty Business Unit includes revenue from products other than from cancer treatment products generated by Daiichi Sankyo Europe GmbH.

Revenue from the Unit in local currency decreased by EUR5 million, or 0.6%, to EUR809 million due to decreases in sales of Lixiana and others, despite the growth of Nilemdo/Nustendi. On the other hand, on a JPY basis, revenue was JPY149.2 billion, constituting an increase of JPY12.4 billion, or 9.1% year on year, due to the effect from foreign exchange by the depreciation of JPY.

f. ASCA Business Unit

Revenue from ASCA^{*1} Business Unit includes sales to overseas licensees.

Revenue from the Unit increased by JPY24.6 billion, or 20.9% year on year, to JPY142.5 billion due to the growth in sales of Enhertu in Brazil and other factors.

^{*1} Asia, South & Central America

The following describes the major progress in the first six months of the year ending March 31, 2027.

- In August 2026, approval was obtained for Enhertu in China for the combination therapy with pertuzumab for the first-line treatment for HER2 positive breast cancer, and the promotion started.

2) Status of R&D

The Group focuses on accelerating global clinical development and intensively allocates resources to 5DXd ADCs^{*1} (trastuzumab deruxtecan, datopotamab deruxtecan, patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan) for maximizing their product values, and aims to create products that change SOC^{*2} (Next Wave).

Furthermore, based on the knowledge and achievements gained from DXd ADC, we are advancing R&D in deepening ADC technology as well as in multiple modalities^{*3} beyond ADC.

To achieve sustainable growth, we aim to identify several Breakthrough Generating Technologies (BGTs)^{*4} by the fiscal year 2030, following DXd ADC, through these initiatives that leverage our strengths in science and technology.

^{*1} ADC: Abbreviation for Antibody Drug Conjugate, drug composed of an antibody and a payload (a small molecule compound) linked via appropriate linker. By using an antibody that binds to a specific target expressed on cancer cells, a cytotoxic payload is delivered to cancer cells effectively with reducing systemic exposure. DXd ADCs are drugs that combine the Company's proprietary drugs and linkers with antibodies.

^{*2} Standard of Care: Universally applied best treatment practice in today's medical science.

- *3 Modality: Medical treatment such as small molecule drugs, antibody drugs, ADC, nucleic acid drugs and gene therapy.
- *4 BGT: A drug discovery technology platform designed to deliver more innovative medicines to patients faster.

[5DXd ADCs]

The following describes the Group's clinical development of 5DXd ADCs projects in the first six months of the year ending March 31, 2027 (from April 1, 2026 to September 30, 2026). The status of each clinical trial is stated in the Reference Data.

The Group is developing trastuzumab deruxtecan and datopotamab deruxtecan jointly with AstraZeneca. In addition, the Group is developing patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan jointly with Merck & Co., Inc., Rahway, NJ, USA (hereinafter "Merck in the U.S.").

a. Trastuzumab deruxtecan (T-DXd/DS-8201: HER2-directed ADC, brand name: Enhertu)

The following describes the major progress in the first six months of the year ending March 31, 2027.

- In May 2026, the application was approved in the U.S. for neoadjuvant therapy targeting stage II or stage III HER2 positive breast cancer, involving combination therapy with taxane, trastuzumab, and pertuzumab (THP) following administration of ENHERTU.
- In May 2026, the application was approved in the U.S. for adjuvant therapy targeting HER2 positive breast cancer with residual invasive disease after neoadjuvant therapy with anti-HER2 therapy.
- In May 2026, the application was recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for unresectable or metastatic HER2 positive (IHC 3+) solid tumors with prior treatment history and no alternative treatment options.
- In June 2026, the application was approved in Europe for unresectable or metastatic HER2 positive (IHC 3+) solid tumors with prior treatment history and no alternative treatment options.
- In July 2026, the application was recommended for approval by the EMA's CHMP for the combination therapy with pertuzumab for the first-line treatment of HER2 positive (IHC 3+ or ISH+) breast cancer.
- In August 2026, the application was approved in China for the combination therapy with pertuzumab for the first-line treatment of HER2 positive breast cancer.
- In August 2026, the outline of the data from the Phase III clinical trial for the first-line treatment of non-small cell lung cancer (NSCLC) with HER2 gene mutations (trial name: DESTINY-Lung04) was presented.
- In September 2026, the application was approved in Europe for the combination therapy with pertuzumab for the first-line treatment of HER2 positive (IHC 3+ or ISH+) breast cancer.
- In September 2026, the major analysis data of the DESTINY-Lung04 clinical trial was presented at the World Conference on Lung Cancer (WCLC).
- In September 2026, the application was approved in Japan for the combination therapy with pertuzumab for the first-line treatment of HER2 positive breast cancer.
- In September 2026, the application was recommended for approval by the EMA's CHMP for adjuvant therapy targeting HER2 positive breast cancer with residual invasive disease after neoadjuvant therapy with taxane-based therapy and anti-HER2 therapy.

b. Datopotamab deruxtecan (Dato-DXd/DS-1062: TROP2-directed ADC, brand name: Datroway)

The following describes the major progress in the first six months of the year ending March 31, 2027.

- In May 2026, the application was approved in the U.S. for the first line treatment for triple-negative breast cancer (TNBC) not eligible for PD-1/PD-L1 inhibitor therapy.
- In June 2026, the application was recommended for approval by the EMA's CHMP for the first line treatment for TNBC not eligible for PD-1/PD-L1 inhibitor therapy.
- In July 2026, the application was approved in Europe for the first-line treatment for TNBC not eligible for PD-1/PD-L1 inhibitor therapy.
- In August 2026, the Phase III clinical trial to evaluate the combination therapy with rilvegostomig and the monotherapy as adjuvant therapy for muscle invasive urothelial cancer at high risk of recurrence (trial name: TROPION-Urothelial04) was initiated.
- In September 2026, the application was approved in Japan for the first-line treatment of hormone receptor-negative and HER2-negative breast cancer^{*5}.

^{*5} The approval was based on the results from the Phase III clinical trial (trial name: TROPION-Breast02).

c. Ifinatamab deruxtecan (I-DXd/DS-7300: B7-H3-directed ADC)

The following describes the major progress in the first six months of the year ending March 31, 2027.

- In April 2026, the application for approval for the treatment of extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy was accepted and Priority Review Designation^{*6} was granted in the U.S.
- In September 2026, the application for approval for the treatment of extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy^{*7} was voluntarily withdrawn in the U.S.

^{*6} In the U.S., this designation is granted to medicines that provide significant improvements in treatment or offer treatment options for diseases with no currently appropriate therapy. If granted, the review period can be expected to be shorter (targeted 6 months), compared to standard applications review period (targeted 10 months).

^{*7} The application for approval was based on the results from the Phase II clinical trial (trial name: IDEate-Lung01).

[Next Wave]

The following describes the major progress in the Next Wave in the first six months of the year ending March 31, 2027. The status of each clinical trial is stated in the Reference Data.

- In April 2026, the Phase I clinical trial of DS2001 (anti-ORAI1 antibody) in healthy adults was initiated.
- In May 2026, the application was approved in Japan for VN-0102/JVC-001 (freeze-dried live attenuated measles, mumps, rubella combined vaccine, brand name: MIMRIT for Subcutaneous Injection) for the prevention of measles, mumps, and rubella.
- In June 2026, the application was approved in China for quizartinib (AC220: FLT3 inhibitor, brand name: VANFLYTA) for the first-line treatment of acute myeloid leukemia with FLT3-ITD mutations.
- In August 2026, the Phase I clinical trial of DS1025 (CD25-directed ADC) for solid tumors was initiated.

(2) Analysis of Financial Position as of September 30, 2026

- Total assets as of September 30, 2026 were JPY4,258.6 billion, an increase of JPY262.3 billion from the previous fiscal year-end, mainly due to increases in cash and cash equivalents, inventories and property, plant and equipment, which were partially offset by decreases in other financial assets (current assets) and trade and other receivables.
- Total liabilities as of September 30, 2026 were JPY2,478.5 billion, an increase of JPY166.3 billion from the previous fiscal year-end, mainly due to an increase in bonds and borrowings (non-current liabilities), which was partially offset by a decrease in income taxes payable.
- Total equity as of September 30, 2026 was JPY1,780.1 billion, an increase of JPY96.1 billion from the previous fiscal year-end, mainly due to profit for the period, which was partially offset by cash dividend payment.
- The ratio of equity attributable to owners of the Company to total assets was 41.3%, a decrease of 0.8 points from the previous fiscal year-end.

(3) Information about Forecasts of Consolidated Financial Results and Other Forward-Looking Statements

- There are no changes from the forecasts of consolidated financial results for the year ending March 31, 2027, publicly announced on July 31, 2026.

(4) Information about Return to Shareholders

- In order to secure sustainable growth in corporate value, one of the fundamental business policies of Daiichi Sankyo is to decide profit distributions based on a comprehensive consideration of the investments essential for implementing its growth strategy and returning profits to shareholders.
- In the new Five-Year Business Plan (fiscal 2026-fiscal 2030), the Company will adopt a progressive dividend policy under which dividends will continue in principle to be maintained or increased and has set an adjusted DOE of 10.0% or more per fiscal year as a benchmark for the dividend level.
- In addition to dividends, the acquisition of own shares is also positioned as an option for shareholder returns. While prioritizing progressive dividends, the Company will consider implementing the acquisition of own shares flexibly, based on a comprehensive assessment of its financial condition, market environment, and other relevant factors.

<Stable dividend payment>

- For fiscal 2025, the Company paid a year-end dividend of JPY39 per share on June 23, 2026. Accordingly, the annual dividend for the fiscal year, together with the interim dividend of JPY39 per share paid on December 10, 2025, was JPY78 per share in total.
- For fiscal 2026, the Company intends to pay the annual dividend of JPY100 per share, an increase of JPY22 from the annual dividend of fiscal 2025, in order to enhance shareholder returns and support further growth under the new 5-Year Business Plan. At the Board of Directors meeting held on October 30, 2026, the Company has resolved to pay an ordinary dividend of JPY50 per share as an interim dividend. The interim dividend will be paid on December 10, 2026 to shareholders of record as of September 30, 2026.

<Cancellation of own shares>

- From May 1, 2025 to March 24, 2026, the Company established upper limits of JPY200.0 billion or 80 million shares for acquisition of its own shares. All shares acquired during this period (31.45 million shares) were canceled on June 10, 2026.

2. Condensed Interim Consolidated Financial Statements with Primary Notes

(1) Condensed Interim Consolidated Statement of Financial Position

(Millions of JPY)

	As of March 31, 2026	As of September 30, 2026
ASSETS		
Current assets		
Cash and cash equivalents	449,807	680,843
Trade and other receivables	741,145	700,973
Other financial assets	104,736	48,839
Inventories	692,378	796,888
Other current assets	32,279	44,192
Subtotal	2,020,346	2,271,737
Assets held for sale	122,162	113,021
Total current assets	2,142,509	2,384,758
Non-current assets		
Property, plant and equipment	596,563	635,282
Goodwill	97,353	96,321
Intangible assets	241,064	229,191
Investments accounted for using the equity method	4,918	5,024
Other financial assets	194,435	215,570
Long-term advance payments	192,906	178,463
Deferred tax assets	456,195	473,885
Other non-current assets	70,338	40,129
Total non-current assets	1,853,775	1,873,867
Total assets	3,996,285	4,258,626

(Millions of JPY)

	As of March 31, 2026	As of September 30, 2026
LIABILITIES AND EQUITY		
Liabilities		
Current liabilities		
Trade and other payables	567,898	612,243
Bonds and borrowings	404	406
Other financial liabilities	13,630	14,318
Income taxes payable	88,303	57,757
Provisions	49,811	57,941
Contract liabilities	74,405	77,933
Other current liabilities	30,060	28,898
Subtotal	824,513	849,498
Liabilities directly associated with assets held for sale	31,552	33,278
Total current liabilities	856,065	882,777
Non-current liabilities		
Bonds and borrowings	300,077	499,927
Other financial liabilities	39,219	36,639
Post-employment benefit liabilities	1,452	1,856
Provisions	164,572	144,792
Contract liabilities	806,809	787,504
Deferred tax liabilities	3,230	2,996
Other non-current liabilities	140,825	122,010
Total non-current liabilities	1,456,186	1,595,727
Total liabilities	2,312,252	2,478,504
Equity		
Equity attributable to owners of the Company		
Share capital	50,000	50,000
Own shares	(247,993)	(137,908)
Other components of equity	311,619	301,935
Retained earnings	1,570,407	1,543,621
Total equity attributable to owners of the Company	1,684,033	1,757,648
Non-controlling interests	–	22,472
Total equity	1,684,033	1,780,121
Total liabilities and equity	3,996,285	4,258,626

(2) Condensed Interim Consolidated Statement of Profit or Loss and Condensed Interim Consolidated Statement of Comprehensive Income

Condensed Interim Consolidated Statement of Profit or Loss

(Millions of JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Revenue	975,353	1,167,233
Cost of sales	248,327	245,798
Gross profit	727,026	921,435
Selling, general and administrative expenses	369,432	487,712
Research and development expenses	217,672	240,055
Other income	4,316	133
Other expenses	0	4
Operating profit	144,237	193,795
Financial income	20,453	16,145
Financial expenses	2,253	17,357
Share of profit (loss) of investments accounted for using the equity method	780	271
Profit before tax for the period	163,217	192,855
Income taxes	32,403	39,799
Profit for the period	130,814	153,056
Profit attributable to:		
Owners of the Company	130,814	151,534
Non-controlling interests	–	1,521
Profit for the period	130,814	153,056
Earnings per share		
Basic earnings per share (JPY)	70.55	83.22
Diluted earnings per share (JPY)	70.52	83.20

Condensed Interim Consolidated Statement of Comprehensive Income

(Millions of JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit for the period	130,814	153,056
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	3,605	4,443
Remeasurements of defined benefit plans	0	–
Items that are or may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	5,011	(13,821)
Cash flow hedges	77	–
Total other comprehensive income for the period, net of tax	8,695	(9,377)
Total comprehensive income for the period	139,509	143,679
Total comprehensive income attributable to:		
Owners of the Company	139,509	142,152
Non-controlling interests	–	1,526
Total comprehensive income for the period	139,509	143,679

(3) Condensed Interim Consolidated Statement of Changes in Equity

Six months ended September 30, 2026

(Millions of JPY)

	Equity attributable to owners of the Company						
	Other components of equity						Financial assets measured at fair value through other comprehensive income
	Share capital	Capital surplus	Own shares	Subscription rights to shares	Exchange differences on translation of foreign operations	Cash flow hedges	
Balance as of April 1, 2025	50,000	—	(147,321)	424	228,137	—	35,130
Profit for the period	—	—	—	—	—	—	—
Other comprehensive income for the period	—	—	—	—	5,011	77	3,605
Total comprehensive income for the period	—	—	—	—	5,011	77	3,605
Purchase of own shares	—	(52)	(58,488)	—	—	—	—
Disposal of own shares	—	—	316	(5)	—	—	—
Cancellation of own shares	—	(3,582)	48,971	—	—	—	—
Dividend	—	—	—	—	—	—	—
Share-based compensation	—	3,634	164	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	—	—	—	—	(1,067)
Transfer to non-financial assets and similar items	—	—	—	—	—	(77)	—
Others	—	—	—	—	—	—	—
Total transactions with owners of the Company	—	—	(9,037)	(5)	—	(77)	(1,067)
Balance as of September 30, 2025	50,000	—	(156,358)	419	233,149	—	37,668

(Millions of JPY)

	Equity attributable to owners of the Company				
	Other components of equity		Retained earnings	Total equity attributable to owners of the Company	Total equity
	Remeasurements of defined benefit plans	Total other components of equity			
Balance as of April 1, 2025	—	263,693	1,457,044	1,623,416	1,623,416
Profit for the period	—	—	130,814	130,814	130,814
Other comprehensive income for the period	0	8,695	—	8,695	8,695
Total comprehensive income for the period	0	8,695	130,814	139,509	139,509
Purchase of own shares	—	—	—	(58,540)	(58,540)
Disposal of own shares	—	(5)	(39)	271	271
Cancellation of own shares	—	—	(45,388)	—	—
Dividend	—	—	(56,053)	(56,053)	(56,053)
Share-based compensation	—	—	—	3,798	3,798
Transfer from other components of equity to retained earnings	(0)	(1,068)	1,068	—	—
Transfer to non-financial assets and similar items	—	(77)	—	(77)	(77)
Others	—	—	365	365	365
Total transactions with owners of the Company	(0)	(1,150)	(100,047)	(110,235)	(110,235)
Balance as of September 30, 2025	—	271,237	1,487,811	1,652,690	1,652,690

Six months ended September 30, 2026

(Millions of JPY)

	Equity attributable to owners of the Company					
	Share capital	Capital surplus	Own shares	Other components of equity		
				Subscription rights to shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income
Balance as of April 1, 2026	50,000	—	(247,993)	381	278,494	32,743
Profit for the period	—	—	—	—	—	—
Other comprehensive income for the period	—	—	—	—	(13,821)	4,438
Total comprehensive income for the period	—	—	—	—	(13,821)	4,438
Purchase of own shares	—	—	(483)	—	—	—
Disposal of own shares	—	(2,490)	3,351	(301)	—	—
Cancellation of own shares	—	(100,687)	100,687	—	—	—
Dividend	—	—	—	—	—	—
Share-based compensation	—	(2,862)	6,530	—	—	—
Changes in ownership interests in subsidiaries	—	—	—	—	—	—
Transfer from retained earnings to capital surplus	—	106,040	—	—	—	—
Others	—	—	—	—	—	—
Total transactions with owners of the Company	—	—	110,084	(301)	—	—
Balance as of September 30, 2026	50,000	—	(137,908)	80	264,673	37,181

(Millions of JPY)

	Equity attributable to owners of the Company				
	Other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
	Total other components of equity				
Balance as of April 1, 2026	311,619	1,570,407	1,684,033	—	1,684,033
Profit for the period	—	151,534	151,534	1,521	153,056
Other comprehensive income for the period	(9,382)	—	(9,382)	5	(9,377)
Total comprehensive income for the period	(9,382)	151,534	142,152	1,526	143,679
Purchase of own shares	—	—	(483)	—	(483)
Disposal of own shares	(301)	—	559	—	559
Cancellation of own shares	—	—	—	—	—
Dividend	—	(71,175)	(71,175)	—	(71,175)
Share-based compensation	—	—	3,667	—	3,667
Changes in ownership interests in subsidiaries	—	—	—	20,946	20,946
Transfer from retained earnings to capital surplus	—	(106,040)	—	—	—
Others	—	(1,105)	(1,105)	—	(1,105)
Total transactions with owners of the Company	(301)	(178,320)	(68,537)	20,946	(47,591)
Balance as of September 30, 2026	301,935	1,543,621	1,757,648	22,472	1,780,121

(4) Condensed Interim Consolidated Statement of Cash Flows

(Millions of JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before tax	163,217	192,855
Depreciation and amortization	36,689	43,351
Impairment losses (reversal of impairment losses)	1,127	2,969
Financial income	(20,453)	(16,145)
Financial expenses	2,253	17,357
Share of (profit) loss of investments accounted for using the equity method	(780)	(271)
(Gain) loss on sale and disposal of non-current assets	819	452
(Increase) decrease in trade and other receivables	14,325	28,757
(Increase) decrease in inventories	(77,826)	(108,816)
(Increase) decrease in long-term advance payments	(50,416)	14,442
Increase (decrease) in trade and other payables	(40,307)	12,257
Increase (decrease) in provisions	18,717	(11,139)
Increase (decrease) in contract liabilities	(16,934)	(15,696)
Others, net	3,630	(7,875)
Subtotal	34,063	152,498
Interest and dividend received	11,384	9,337
Interest paid	(755)	(2,494)
Income taxes paid	(73,004)	(108,601)
Net cash flows from (used in) operating activities	(28,311)	50,738
Cash flows from investing activities		
Payments into time deposits	(24,061)	(5,563)
Proceeds from maturities of time deposits	3,414	33,607
Acquisition of securities	(39,663)	(43,386)
Proceeds from sale and redemption of securities	90,672	68,175
Acquisition of property, plant and equipment	(67,289)	(67,370)
Proceeds from sale of property, plant and equipment	9	75
Acquisition of intangible assets	(11,869)	(6,666)
Proceeds from sale of subsidiaries and affiliates	7,250	73,950
Others, net	(2,069)	(1,344)
Net cash flows from (used in) investing activities	(43,607)	51,476

(Millions of JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from financing activities		
Proceeds from bonds and borrowings	100,000	200,000
Repayments of bonds and borrowings	(200)	(202)
Purchase of own shares	(58,540)	(483)
Proceeds from sale of own shares	0	345
Dividend paid	(56,017)	(71,102)
Repayments of lease liabilities	(7,824)	(11,810)
Others, net	0	0
Net cash flows from (used in) financing activities	(22,583)	116,746
Net increase (decrease) in cash and cash equivalents	(94,502)	218,961
Cash and cash equivalents at the beginning of the period (Condensed interim consolidated statement of financial position)	639,838	449,807
Cash and cash equivalents reclassified back from assets held for sale	–	39,176
Cash and cash equivalents at the beginning of the period	639,838	488,983
Effect of exchange rate changes on cash and cash equivalents	(3,178)	(9,354)
Cash and cash equivalents at the end of the period	542,157	698,590
Cash and cash equivalents reclassified to assets held for sale	–	(17,746)
Cash and cash equivalents at the end of the period (Condensed interim consolidated statement of financial position)	542,157	680,843

(5) Notes to Condensed Interim Consolidated Financial Statements

Going Concern Assumption

Not applicable.

Changes in Presentation

(Condensed Interim Consolidated Statement of Cash Flows)

“Increase (decrease) in provisions”, which was included in “Others, net” under cash flows from operating activities for the first six months of the fiscal year ended March 31, 2026, has been disclosed separately from the first six months of the fiscal year ending March 31, 2027, since the monetary significance has increased.

To reflect this change in presentation, the Condensed Interim Consolidated Statement of Cash Flows for the first six months of the fiscal year ended March 31, 2026, has been reclassified on a consistent basis. As a result, a portion of the amount reported in "Others, net" under cash flows from operating activities in the Condensed Interim Consolidated Statement of Cash Flows for the first six months of the fiscal year ended March 31, 2026, amounting to JPY18,717 million has been reclassified as "Increase (decrease) in provisions" under cash flows from operating activities.

Operating Segment Information

Disclosure is omitted as the Group has a single segment, “Pharmaceutical Operation”.

Significant Subsequent Events

Issuance of unsecured corporate bonds

The Company issued unsecured corporate bonds on October 9, 2026.

(1) Type of bonds issued, issue price, total amount of issue, interest rate, redemption methods, maturity date

a. Type of bonds issued

11th series of unsecured corporate bonds (with limited inter-bond pari passu clause)

12th series of unsecured corporate bonds (with limited inter-bond pari passu clause)

13th series of unsecured corporate bonds (with limited inter-bond pari passu clause)

b. Issue price

JPY100 per JPY100 of the principal amount for each corporate bond

c. Total amount of issue

11th series of unsecured corporate bonds JPY37,000 million

12th series of unsecured corporate bonds JPY45,000 million

13th series of unsecured corporate bonds JPY34,000 million

d. Interest rate

11th series of unsecured corporate bonds 2.410% per annum

12th series of unsecured corporate bonds 2.821% per annum

13th series of unsecured corporate bonds 3.161% per annum

e. Redemption methods

Each corporate bond will be redeemed at face value on the maturity date. Buyback and cancellation are permitted at any time after the payment date.

f. Maturity date

11th series of unsecured corporate bonds 3 years (October 9, 2029)

12th series of unsecured corporate bonds 5 years (October 9, 2031)

13th series of unsecured corporate bonds 7 years (October 7, 2033)

(2) Date of issuance

October 9, 2026 (the payment date is also the same day).

(3) Security or guarantee

The corporate bonds are unsecured and unguaranteed, and no assets are specifically reserved as security for the corporate bonds.

(4) Use of funds procured

Working capital

(5) Special provisions

The corporate bonds are subject to a negative pledge clause.